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1ABSTRACT
Epigenetic downregulation of miRNA-34a and miRNA-449a induce 
epithelial-mesenchymal transition and acquired resistance to 
ceritinib
Sun Min Lim
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Byoung Chul Cho)
Treatment with ALK tyrosine kinase inhibitors often elicits profound initial 
antitumor responses in ALK fusion-positive patients with lung 
adenocarcinoma. However, patients invariably develop acquired resistance to 
ALK inhibitors. Although the recent functional genetic studies characterized 
the mechanism of resistance to ALK inhibition, epigenetic mechanism of 
acquired resistance is poorly understood. Here we report histone H3 lysine 27 
acetylation (H3K27ac) and microRNAs involved in acquired resistance to 
ceritinib, a second generation ALK inhibitor. Epithelial-to-mesenchymal 
transition with AXL activation was found in multiple in vitro and in vivo
ALK-rearranged lung cancer models with acquired resistance to ceritinib. 
Genome-wide analysis identified that miR-34a and miR-449a are decreased 
2with loss of H3K27ac and AXL and mesenchymal genes are increased in the 
process of acquired resistance. Pharmacological inhibition of AXL or ectopic 
expression of miR-34a or miR-449a restored sensitivity to ceritinib in 
resistant cells. We also found histone deacetylase inhibitor, panobinostat, 
synergistically induced anti-proliferative effects with ceritinib in resistant 
cells. Our findings demonstrate that H3K27ac remodeling is a crucial event in 
ceritinib resistance and inhibition of both ALK and HDAC could prevent or 
overcome acquired resistance to ALK inhibitors in individuals with 
ALK-rearranged lung cancer.
--------------------------------------------------------------------------------------
Key words: non-small-cell lung cancer, acquired resistance, ceritinib, 
epigenetics
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I. INTRODUCTION
EML4-ALK rearrangement is a distinct molecular subclassification of 
non-small-cell lung cancer (NSCLC).1 It accounts for 4-8% of NSCLC and 
tumors with oncogenic ALK rearrangements are exquisitely sensitive to ALK 
blockade with tyrosine kinase inhibitors (TKIs) 2. Compared with traditional 
chemotherapeutic drugs, treatment with ALK TKIs result in dramatic initial 
response with substantial duration. Crizotinib is the first FDA approved 
treatment for patients with ALK-positive NSCLC3. For 1st line treatment of 
crizotinib, the progression-free survival (PFS) is 10.9 months, and the overall 
response rate (ORR) is 74% 3. However, ALK-positive tumors eventually 
develop acquired resistance to ALK TKIs within 1 year of treatment, 
4manifested by disease progression and leading to dismal prognosis. Ceritinib 
(LDK378) is a potent second-generation ALK inhibitor which can overcome 
resistance to crizotinib. The anticancer activity of ceritinib was shown in a 
phase I study for patients with ALK-positive NSCLC where the objective 
response rate was 58% for the 114 patients who were treated with ceritinib at 
doses above 400mg per day 4. For patients previously treated with crizotinib, 
the response rate was 56%. Based on these findings, ceritinib has been granted 
FDA approval for treatment of patients with ALK-positive NSCLC in the 
second-line setting following failure or intolerance to crizotinib.
To date, two distinct mechanisms (ALK-dependent, ALK-independent) of 
acquired resistance to ALK TKIs have been known. A secondary mutation in 
kinase domain of ALK gene hinders the binding of ALK TKI. Unlike the 
situation with EGFR T790M mutation which is observed in approximately 
50% of NSCLC tumors bearing activating mutations in the EGFR gene, the 
secondary mutations associated with ALK are diverse over a number of 
locations on the kinase domain5. Gatekeeper mutations such as L1196M, 
L1152R, C1156Y, and F1174L are frequently detected in crizotinib-resistant 
samples6. To date, up to one-third of patients who are progressing on 
crizotinib harbor resistant mutations. Friboulet and colleagues reported 
resistance mechanisms to ceritinib in a cohort of 11 patients who underwent 
biopsy at emergence of resistance to ceritinib 7. None harbored the gatekeeper 
mutations which suggest the complexity of acquired resistance. Other 
5mechanisms of resistance are activated bypass signaling pathways (EGFR, 
KRAS, KIT, MET and IGF-1R), which allow continuous cell proliferation and 
survival8-10, and epithelial to mesenchymal transition signature11, 12.  
While genomic mechanisms of acquired resistance have been identified, 
epigenomic mechanisms of ALK TKI resistance have not been elucidated. 
Epigenetic alterations accumulate in the noncoding genome throughout 
oncogenesis 13. These involve DNA methylation or histone modification 
which can control expression of miRNAs and alter gene expressions involved 
in drug sensitivity. Previous studies have implicated that tumors exhibit not 
only genetic but also epigenetic heterogeneity within cell populations and that 
acquisition of epigenetic modifications may lead to drug resistance 14, 15. In a 
study by Settleman et al., drug-tolerant tumor cells emerged after altered 
chromatin state, which was reversible with histone deacetylase inhibitor16. 
MicroRNAs (miRNAs), a family of small, non-coding RNAs, function as 
gene expression regulators at posttranscriptional level17. They result in mRNA 
destabilization and translational repression 18, 19, and it is estimated that more 
than 30% of protein expression is regulated by endogenous miRNAs 20. 
MiRNA expression was observed to be linked with tumor response to 
chemotherapies 21, 22, and their role in ALK-rearranged NSCLC remains to be 
identified. However, understanding the alterations in noncoding genome has 
been overlooked and research is especially lacking with regard to acquired 
resistance to ALK TKIs. 
6In this study, we attempted to investigate epigenetic mechanisms underlying 
acquired resistance to ALK TKI. Ultimately, we aimed to explore novel 
strategies to overcome resistance to second-generation ALK TKI.
II. MATERIALS AND METHODS
1. Generation of resistant cells
To create ceritinib-resistant lines, H3122 and H2228 cells were cultured 
with increasing concentrations of ceritinib starting with the one-third 
maximum inhibitory concentration (IC30). Doses were increased in a stepwise 
pattern when normal cell proliferation patterns resumed. Fresh drug was 
added every 72-96h. Resistant cells (H3122-LR and H2228-LR) that grew in 
1µM ceritinib were derived after approximately 6 months of culturing in the 
continuous presence of drug. Real-time PCR showed that both the parental 
and resistant cells confirmed that the cells were derived from the same origin. 
Resistant cells were maintained initially as polyclonal populations under 
constant TKI selection.
2. Growth inhibition assay
For MTT assay, cultured cells were seeded into 96-well plates. Twenty-four 
hours after seeding, various concentrations of ceritinib were added to the 
culture. After 72hr, 50μl of MTT (5mg/ml stock solution) was added and the 
7plates were incubated for additional 4hr. The medium was discarded and the 
formazan blue, which was formed in the cells, was dissolved with 100 µl 
DMSO. The optical density was measured at 540 nm. Relative survival in the 
presence of drugs was normalized to DMSO control cells after background 
subtraction. For colony formation assays, cells were seeded into 6-well plates 
(2.5 x 104 cells per well) and treated with the agents in RMPI-1640 containing 
10% FBS for 14 days. Compound treatments were replaced at least every 3 
days during the assay. After 14 days, cells were fixed in 3% paraformaldehyde 
in phosphate buffered saline (PBS) for 10 min at room temperature and 
stained with 0.5% crystal violet in 20% methanol for 20 min. Images were 
captured using flatbed scanner, and the cells were dissolved with 20% acetic 
acids in 20% methanol for 30 min. Assays were performed independently at 
least three times.
3. Western blot analysis
Preparation of whole cell protein lysates and western blot analysis were 
described previously. Briefly, cells were then chilled on ice, washed twice 
with ice-cold PBS, and lysed in a buffer (Cell Signaling Technology, Beverly, 
MA, USA) containing 1 mM PMSF and 1X protease inhibitors (Sigma 
Aldrich). Protein concentrations were determined using a Bradford assay kit 
(Bio-Rad Laboratories). Equal amounts of protein in cell lysates were 
separated by SDS-PAGE, transferred to membranes, immunoblotted with 
8specific primary and secondary antibodies, and the blot was detected by 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher 
Scientific), according to the manufacturer's instructions.
4. Phospho-receptor tyrosine kinase assay
The Human Phospho-Kinase Array Kit (R&D Systems) was used to detect 
the activation of 49 different protein kinases mediating various aspects of 
cellular proliferation following the manufacturer’s instructions. Briefly, 
H3122-LR cells were plated in 10-cm dishes and cultured at 37 °C for 28 h. 
After cell lysis, 500 μg of lysate was applied to a membrane-anchored 
phosphor kinase array and incubated at 4 °C for 24hrs. Membranes were 
exposed to chemiluminescent reagents and detected by X-ray film (AGFA).
5. Quantitative RT-PCR
Total RNA was isolated from cells using an RNeasy Mini Kit (Qiagen). The 
RNA was subjected to reverse transcription using the High-Capacity 
RNA-to-cDNA Kit (Life Technologies), according to the manufacturer’s 
protocol. Quantitative RT-PCR (qRT-PCR) was performed using the 
fluorescent SYBR Green dye methodology and an ABI Prism 7000 Sequence 
Detection System (Life Technologies). 
6. cDNA sequencing of ALK
9Total RNA was isolated from cell pellets using the RNeasy mini kit (Qiagen, 
Germantown, MD, USA). The SuperScript III one-step RT-PCR system with 
platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA) was used to 
perform both cDNA synthesis and PCR amplification with gene-specific 
primers: EML4 E18F (aligned on EML4 exon 13, 
5’-TTAGCATTCTTGGGGAATGG-3’) and ALK_kinase_domain_R 
(5’-GCCTGTTGAGAGACCAGGAC-3’). The 1,223-bp PCR product, which 
includes the EML4-ALK fusion point and the entire ALK kinase domain, was 
sequenced in both directions by Sanger dideoxynucleotide sequencing. 
7. Generation of in vivo resistant model
Human H3122 cells were injected subcutaneously into the flanks of CB17 
SCID mice. Tumor-bearing mice (tumor size 200-500mm3) were treated with 
LDK378 (50mg/kg, 75mg/kg, 87.5mg/kg, 100mg/kg) administered daily. 
Tumors initially showed dose-dependent decrease in volume following 
LDK378 treatment and when tumors showed > 30% regrowth from maximal 
reduction, mice were sacrified to collect tumor tissue. All animal experiments 
were performed in compliance with the worldwide standard animal care 
condition via Institutional Animal Care and Use Committee (IACUC). The 
research proposal was approved by Yonsei University IACUC.
8. Microarray analysis
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Total RNA was extracted using RNeasy columns (Qiagen, Valencia, USA) 
according to the manufacturer’s protocol. RNA purity and integrity were 
evaluated by ND-1000 Spectrophotometer (NanoDrop), Agilent 2100 
Bioanalyzer (Agilent Technologies). Total RNA was amplified and purified 
using TargetAmp-Nano Labeling Kit for Illumina Expression Bead Chip 
(EPICENTER) to yield biotinylated cRNA according to the manufacturer’s 
instructions. Briefly, 200~500ng of total RNA was reverse-transcribed to 
cDNA using a T7 oligo (dT) primer. Second-strand cDNA was synthesized, in 
vitro transcribed, and labeled with biotin-NTP. After purification, the cRNA 
was quantified using the ND-1000 Spectrophotometer. 750ng of labeled 
cRNA samples were hybridizaed to each HumanHT-12 v4.0 Expression 
Beadchip for 16-18h at 58˚C, according to the manufacturer’s instructions 
(Illumina, Inc.). Detection of array signal was carried out using 
Amershamfluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences) 
following the bead array manual. Arrays were scanned with an Illumina bead 
array Reader confocal scanner according to the manufacturer’s instructions. 
9. MBD-sequencing
MBD-seq was performed as described 23. Methylated DNA was precipitated 
using the MethylMiner methylated DNA enrichment kit (Invitrogen). The 
purified methylated DNA fragments were ligated to a pair of adaptors for 
sequencing on the Illumina NextSeq500. Single-end reads (75 bp) were 
11
aligned against the human reference genome 19 with the BWA aligner 24. The 
MEDIPS R package (v. 1.18.0) was used for the analysis of MBD-seq data 
and DMR identification 25. The Homer (v.4.8.2) software was used for the 
annotation of peaks and assessment of the distribution of methylation peaks 
across samples.
10. ChIP-sequencing
ChIP-sequencing was performed as described 26. Cells were fixed using 1% 
formaldehyde, lysed and sonicated using a Bioruptor (Diagenode Inc.). 
Immunoprecipitation was performed with anti-H3K27ac (Millipore, 06-599) 
or anti-H3K4me1 (Abcam, ab8895). 250-400 bp genomic libraries were 
generated from the input and immunoprecipitated DNA and sequenced using 
Illumina NextSeq500 to generate 75 bp single-end reads. The sequencing 
reads were also aligned to the reference sequence (hg 19) using the Bowtie2 
(v.2.2.2) software. Finding, estimation and annotation of ChIP-seq peaks were 
carried out by the Homer (v.4.8.2) platform 27.
11. RNA-sequencing
RNA-seq was performed as described 26. The RNA sequencing library was 
prepared using the TruSeq RNA Sample Prep Kit (Illumina, San Diego, CA, 
USA) and the sequencing was performed based on Illumina NextSeq500 
platform to generate 75 bp paired-end reads. The sequenced reads were 
12
mapped to the human genome (hg19) using TopHat 2, and the gene expression 
levels were quantified with HTSeq-count module in the HTSeq package 28, 29. 
The edgeR package was used to select differentially expressed genes from the 
RNA-seq count data 30. Meanwhile, the FPKM value of each gene was floored 
to 1, and log2-transformed for further analysis (clustering, heatmap producing 
and correlation analysis). 
12. Small RNA-sequencing
Small RNA libraries were constructed as described previously 31 with some 
modifications. Total RNA was isolated using the mirVana miRNA isolation 
kit (Ambion). Small RNAs (20 - 30 nt) were purified from 15% Novex 
TBE-Urea gel (Invitrogen) and ligated first with the 5’ RNA adaptor and then 
with the 3’ RNA adaptor provided by Illumina TruSeq small RNA sample 
preparation protocol. In each step, the ligated product was PAGE-gel purified. 
After first-strand synthesis and 11 cycles of PCR amplification, the product 
was PAGE-gel purified and submitted for sequencing on an Illumina 
NextSeq500 at LAS (Seoul, Korea; http://www.lascience.co.kr). After TruSeq 
small RNA adapters were eliminated among the sequenced reads by 
Trimommatic software (v.0.33), the remained sequence data were mapped to 
the human genome (hg19) using bowtie2 (v.2.2.2). Similar with the RNA-seq 
analysis procedure, the quantification and significance test were carried out 
using HTSeq and edgeR packages, respectively. 
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13. Data access
Microarray and sequencing data have been deposited in the NCBI Gene 
Expression Omnibus (GEO) under accession number GSE81261(for 
microarray) and GSE81487 (for sequencing data). 
14. Apopercentage apoptosis assay
Apoptosis was detected using an APOPercentage TM kit (Biocolor, Belfast, 
NIreland) as described previously 32. Phosphotidylserine at the outside surface 
of the cell membrane allows the unidirectional transport of the 
APOPercentage dye to the interior of the cell, where it is retained and 
accumulates as a red-dye in apoptotic cells, which can be observed in an 
inverted microscope and measured spectrometrically at 550nm. The treated 
cells in 24- or 96-well culture plates were stained with the APOPercentage 
dye for 1h. The medium was then removed and cells were washed twice with 
PBS. The levels of APOPercentage dye uptake were quantified by the 
colorimetric method according to the manufacturer’s instruction.   
15. Statistical analysis
Statistical analysis was performed using the GraphPad Prism software, 
version 5.0 (GraphPad Software). Student t-test was used for comparisons. All 
P values were two-sided, and values of P < 0.05 were regarded as statistically 
14
significant. 
III. RESULTS
1. Establishment of ALK TKI-resistant cells
For in vitro model, we established ceritinib resistant cell lines (H3122-LR 
and H2228-LR). H3122 and H2228 cells were cultured with ceritinib, 
gradually increasing the concentration to 1μmol/L. After 6 months of 
exposure to ceritinib, H3122 LR and H2228 LR cells were established. Their 
resistance to ceritinib was confirmed by the MTS cell proliferation assay 
(Figure 1A). Ceritinib could not inhibit phospho-ALK and the activation of 
ALK downstream signals, such as Akt and Erk, in both H3122-LR and H2228 
-LR cells (Figure 1B). H3122-LR cells were also resistant to other ALK 
inhibitors, crizotinib and PF06463922, respectively (Figure 1C). We observed 
morphologic differences between the parental cells and resistant cells using a 
light microscope. The round shape of parental cells changed to spindle shaped, 
fibroblast-like shape, suggesting that epithelial-mesenchymal transition 
(EMT)-like changes may have occurred (Figure 1D). 
To clarify the mechanisms of acquired resistance to ceritinib, we first 
performed DNA sequencing of a cDNA representing the ALK tyrosine kinase 
domain to see if known mutations were present. We did not find any 
secondary mutations affecting the ALK tyrosine kinase domain, spanning 
15
exons 21-27. Next, to evaluate the activation of bypass pathways, we 
examined the phosphorylation level of receptor tyrosine kinases, using a 
human phospho-RTK array kit, in H3122-LR cells. Phospho-RTK array 
analysis showed increased phosphorylation of EGFR, HER2, HER3 and AXL 
in H3122-LR and H2228-LR cells, compared with parental cells (Appendix 
1). To confirm this finding, we performed Western blotting of H3122 and 
H3122-LR cells. As expected, the phosphorylation level of AXL (Y702) was 
increased in H3122-LR cells, with concomitant increased level of total AXL 
(Figure 1E). AXL has previously been associated with EMT, and recent 
studies have suggested that therapeutic resistance may be associated with 
histological changes in NSCLC 11, 33, 34. To confirm the induction of EMT in 
resistant cells, we analyzed the expression of epithelial and mesenchymal 
marker proteins using western blots. Compared to parental cells, E-cadherin 
was dramatically reduced, and N-cadherin expression was increased in both 
H3122-LR and H2228-LR cells (Figure 1E).
2. Elevated EMT signature in in vivo resistance model 
For in vivo model, H3122 xenograft established in nude mice were treated 
with four doses of ceritinib (50mg/kg, 75mg/kg, 87.5mg/kg, and 100mg/kg) 
to derive ceritinib-resistant tumors. Xenograft tumors showed initial 
dose-dependent decrease in tumor volume and subsequently developed 
acquired resistance within 24-108 days (Figure 1F, Table 1). Sequencing of 
16
ALK tyrosine kinase domain showed no previously known secondary 
mutations associated with resistance. Next, we conducted microarray 
expression profiling of xenograft tumors to see which genes were 
differentially regulated in the ceritinib-resistant tumors compared to control 
tumors (unpaired t test, P < 0.05). This analysis showed that 30 genes were 
highly expressed in ceritinib-resistant tumors and that EMT-related genes 
were significantly elevated in resistant tumors (Figure 1G). 
Table 1. Treatment response to ceritinib in H3122 tumor xenografts
LDK378 
Maximum 
tumor volume 
reduction
Time to 
maximum 
volume 
reduction
Median time to 
resistancedose
(mg/kg)
50 34.05% 18 days 24 days
75 62.20% 32 days 48 days
87.5 72.98% 42 days 62 days
100 74.25% 42 days 108 days
17
18
Figure 1. Ceritinib-resistant cells exhibit features of 
epithelial-mesenchymal transition with upregulation of AXL. (A) H3122 
LR cells and H2228 LR cells were treated with ceritinib at the indicated 
concentrations, and viable cells were measured after 72 hours of treatment and 
plotted relative to parental cells. (B) H3122 parental, H3122 LR, H2228 
parental, H2228 LR cells were treated with 1μM of ceritinib for 6 hours. Cell 
extracts were immunoblotted to detect the indicated proteins. (C) H3122 
parental, H3122 LR cells were treated with crizotinib and PF-06463922 at the 
indicated concentrations and viable cells were measured after 72 hours of 
treatment. (D) H3122 parental, H3122 LR, H2228 parental, H2228 LR cells 
were observed using a light microscope. (E) H3122 parental, H3122 LR, 
H2228 parental, H2228 LR cell extracts were immunoblotted to detect the 
indicated proteins. (F) Mice with established H3122-derived tumors were 
treated with four doses of ceritinib to derive ceritinib-resistant tumors. (G) 
Microarray expression profiling of xenograft tumors was performed to see 
which genes were differentially regulated in the ceritinib-resistant tumors 
compared to control tumors.
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3. Epigenome and transcriptome remodeling during acquired 
resistance to ceritinib
To investigate the epigenetic mechanisms of AXL activation and EMT 
induction during resistance to ceritinib, we performed methylated DNA 
binding domain sequencing (MBD-seq) for DNA methylation and chromatin 
immunoprecipitation-sequencing (ChIP-seq) for histone modifications 
associated with enhancers (H3K4me1 and H3K27ac) of H3122 and H3122 
LR cells. MBD-seq showed similar level of average DNA methylation 
between H3122 and H3122 LR cells (Figure 2A). Among enhancer signals, 
average level of H3K4me1 was stable, but H3K27ac, the active enhancer 
signal 35, showed up to 22% decrease at the center in H3122 LR cells. A total 
of 52,468 H3K27ac peaks were found in H3122 cells and 11,782 peaks 
(22.4%) were decreased in H3122 LR cells (Figure 2B), suggesting loss of 
enhancer activity during acquired resistance to ceritinib. The regions with loss 
of H3K27ac were associated with protein coding genes (75%), non-coding 
RNAs (18%), and microRNAs (5%) within 10 kb (Figure 2C).
To examine the transcriptome changes in H3122 LR cells, we performed 
RNA sequencing (RNA-seq) in parental and LR cells and identified 802 
up-regulated and 970 down-regulated genes, respectively (fold change > 2) 
(Figure 2D). Cell adhesion related genes (e.g., N-Cadherin, LAMA3, and 
COL5A1) were enriched in up-regulated genes (enrichment score 6.02), 
whereas apoptosis related genes (e.g., IGFBP3, TNFRSF10A, and PDCD2) 
were enriched in down-regulated genes (enrichment score 3.76). In addition to 
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the increased mRNA level of AXL (11-fold up), GAS6, the AXL ligand, was 
also increased (21-fold up). Among the down-regulated genes, 541 genes 
showed loss of H3K27ac. Gene ontology analysis showed that these genes are 
involved in regulation of phosphorylation, cell proliferation, receptor protein 
tyrosine kinase signaling, and apoptosis (Figure 2E). Among these genes, we 
found decreased expression of the MAPK phosphatase, DUSP6 (25-fold 
down), which was previously implicated in RAS-MAPK signaling 
dependent-resistance to ALK inhibitors 36. Another top down-regulated gene 
was the Rho GTPase, RND1 (9-fold down), which is known to suppress EMT 
by retaining Ras-MAPK signaling 37. 
To examine changes in the miRNA expression in H3122 LR cells, we 
performed small RNA-seq and identified 265 up-regulated and 188 
down-regulated miRNAs. miR-221 and miR-222, which promote EMT 38 and 
tumorigenicity by targeting PTEN and TIMP3 tumor suppressors 39, were 
increased in H3122 LR cells. We noted decreased expression of miR-34a 
which regulates AXL expression and promotes EMT 40, and decreased 
expression of miR-449 which contains similar sequences and secondary 
structures as the miR-34 family (Figure 2F) 41. In addition, decreased 
H3K27ac levels of miR-34a were noted in upstream regions of H3122 LR 
cells. 
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Figure 2. Dynamic changes of H3K27ac signal and transcriptome profiles 
in ceritinib resistant cells. (A) Plot of the average H3K27ac level, 
methylation level and H3K4me1 level at all peaks of parental or LR cells. (B) 
Heat maps of H3K27ac in parental and LR cells. 11,782 regions which 
showed decreased H3K27ac level in LR are selected and ranked by the 
difference between parental and LR. Each row represents one peak that is 
centered at the midpoint with a 5-kb flanking sequence. (C) Pie chart 
distribution of loss of H3K27ac region associated gene types. (D) Gene 
ontology analysis for the down-regulated genes with decreased H3K27ac 
levels in LR. (E) Scatter plot of mRNA expression of LR cells compared with 
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parental cells. Red dots indicate a >2-fold increase, and blue dots indicate a > 
2-fold decrease. Positions of the indicated genes are marked by green. (F) 
Scatter plot of miRNA expression of LR cells compared with parental cells. 
Red dots indicate a >2-fold increase, and blue dots indicate a > 2-fold 
decrease. Positions of the indicated miRNAs are marked by green. 
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4. Involvement of miR-34a and miR-449 in AXL-dependent EMT 
gene expression
We examined whether upregulation of AXL is necessary for EMT-related 
changes in LR cells. When AXL inhibitor, foretinib, was treated in H3122 LR 
and H2228 LR cells, inhibition of p-AXL along with upregulation of 
E-cadherin and downregulation of N-cadherin were observed (Figure 3A). 
These data suggest that AXL activation is necessary for the acquisition of 
EMT phenotype in LR cells. 
We observed that relative expression of miR-34a and miR-449 were 
significantly lower in both H3122 and H2228 LR cells, compared to parental 
cells. We next asked whether forced expression of miR-34a and miR-449a 
regulate AXL-dependent EMT gene expression. We first confirmed the activity 
of mimics and inhibitors of miR-34a and miR-449a. Treatment of miR-34a 
and miR-449a mimics in H3122 LR cells induced significant increase in their 
expression, and treatment of inhibitors of miR-34a and miR-449a induced 
significant decrease in their expression (Appendix 2). When mimics of 
miR-34a and miR-449a were treated in H3122 LR cells, p-AXL and 
N-cadherin were downregulated with upregulation of E-cadherin. When 
inhibitors of miR-34a and miR-449a were treated in parental cells, p-AXL and 
N-cadherin were upregulated with downregulation of E-cadherin (Figure 3B). 
These data suggest that miR-34a and miR-449a negatively regulate 
AXL-dependent EMT gene expression in acquired resistance to ceritinib. 
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Figure 3. Involvement of miR-34a and miR-449a in AXL-dependent EMT 
gene expression (A) H3122 parental, H3122 LR, H2228 parental, H2228 LR 
cells were treated with foretinib at the indicated concentrations and 
immunoblotted to detect the indicated proteins. Inhibition of p-AXL along 
with upregulation of E-cadherin and downregulation of N-cadherin were 
observed. (B) Mimics of miR-34a and miR-449a were treated in H3122 LR 
cells, and inhibitors of miR-34a and miR-449a were treated in parental cells. 
Ceritinib 1μM was treated and indicated proteins involving AXL and EMT 
gene expression were immunoblotted. When mimics of miR-34a and 
miR-449a were treated in LR cells, p-AXL and N-cadherin were 
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downregulated with upregulation of E-cadherin. When inhibitors of miR-34a 
and miR-449a were treated in parental cells, p-AXL and N-cadherin were 
upregulated with downregulation of E-cadherin.
Our aim was then to determine whether miR-34a and miR-449a could 
influence ceritinib sensitivity. We investigated whether miR-449a mimics can 
reverse resistance in H3122 LR cells, and whether miR-449a inhibitor can 
confer resistance in H3122 parental cells. As expected, treatment of miR-449a 
mimics re-sensitized H3122-LR cells to ceritinib, and treatment of miR-449a 
inhibitor induced resistance to ceritinib (Figure 4A). Accordingly, treatment 
of miR-34a and miR-449a mimics in LR cells led to decreased p-AKT, and 
p-ERK upon ceritinib treatment. Treatment of miR-34a and miR-449a 
inhibitors in parental cells did not downregulate p-AKT and p-ERK upon 
ceritinib treatment (Figure 4B).  
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Figure 4. MiR-34a and miR-449a affect ceritinib sensitivity. (A) Treatment 
of miR-449a mimics re-sensitized H3122-LR cells to ceritinib, and treatment 
of miR-449a inhibitor induced resistance to ceritinib. (B) Treatment of 
miR-34a and miR-449a mimics in LR cells led to decreased p-AKT, and 
p-ERK upon ceritinib treatment. Treatment of miR-34a and miR-449a 
inhibitors in parental cells did not downregulate p-AKT and p-ERK upon 
ceritinib treatment.
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5. Panobinostat changes H3K27ac profiles and expression of miRNAs
We next examined whether treatment of the histone deacetylase inhibitor 
panobinostat (LBH589) can reverse H3K27ac profiles of LR cells. We 
conducted RNA-seq and ChIP-seq after treatment with panobinostat. We 
found 22,810 regions showing increased H3K27ac level by panobinostat 
treatment (30nM). There was no significant difference in H3K27ac profile 
between combination treatment of panobinostat (30 nM) and ceritinib (10 nM) 
and panobinostat only (Figure 5A). Among the downregulated miRNAs in 
LR cells, 70% maintained low expression levels (e.g., miR-34a, miR-375, and 
miR-29b-2), while 30% showed increased expression level (e.g., miR-449, 
miR-192, and miR-212; Figure 5B). We also found increased expression of 
45 miRNAs which were not decreased in LR cells (e.g., miR-2171, miR-144, 
and miR-184), after panobinostat treatment (Figure 5B). Regardless of 
panobinostat treatment, miR-34a maintained reduced H3K27ac signal (Figure 
5C) and low expression level (Figure 5D). On the contrary, miR-449 showed 
increased H3K27ac signal (Figure 5E) and a significant increase in 
expression level (Figure 5F) with panobinostat treatment. 
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Figure 5. Panobinostat induced changes of H3K27ac signal and miRNAs 
expression (A) Heat maps of H3K27ac in ceritinib resistant cells with 
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panobinostat treatment or panobinostat and ceritinib combination. 22,810 
regions which showed increased H3K27ac level in panobinostat treated cells 
are selected and ranked by the difference between panobinostat treated LR 
and LR. Each row represents one peak that is centered at the midpoint with a 
5-kb flanking sequence. (B) Heat map of relative expression levels of 
miRNAs which were down-regulated with acquired resistance of ceritinib or 
up-regulated with panobinostat treatment. Green represents relatively low 
expression and red, relatively high expression (C) Genome browser view of 
H3K27ac ChIP-seq data of miR-34a in four cells (H3122 parental, H3122 LR, 
panobinostat treated H3122 LR, and panobinostat and ceritinib co-treated 
H3122 LR). (D) qRT-PCR analysis of miR-34a. (E) Genome browser view of 
H3K27ac ChIP-seq data of miR-449a/b/c. (F) qRT-PCR analysis of miR-449a.
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6. HDAC inhibition restores sensitivity to ceritinib in acquired 
resistant cells
Next, we examined whether panobinostat could restore sensitivity to 
ceritinib. Colony formation assays revealed synergistic antitumor effects of 
panobinostat with ceritinib when treated in H3122- and H2228 LR cells and 
the efficacy was dose-dependent (Figure 6A). Apoptosis assay showed 
significant increase in apoptotic cells when H3122- and H2228 LR cells were 
treated with panobinostat or ceritinib plus panobinostat (Figure 6B-C). When 
apoptosis-related markers were examined by western blot, panobinostat
treatment increased phosphorylation of cleaved PARP, cleaved caspase 3, and 
decreased phosphorylation of p21 and cyclin D1 (Figure 6D). Cell cycle 
assay of H3122- and H2228 LR cells showed that ceritinib and panobinostat 
treatment induced arrest of the cells at the G1 phase. (Figure 6E). In addition, 
panobinostat treatment regulated downstream effector genes of miR-34a and 
miR-449a, by downregulating p-AXL, t-MET, and c-MYC. Panobinostat also 
reversed EMT phenotype by downregulating N-cadherin and upregulating 
E-cadherin expression (Figure 6F). 
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Figure 6. Synergistic anti-proliferative effects of panobinostat and 
ceritinib in ceritinib-acquired resistant cells (A) Colony formation assays 
in H3122 parental, H3122 LR, H2228 parental, H2228 LR cells showed 
synergistic anti-proliferative efficacy of ceritinib and panobinostat. (B) 
Apoptosis assay showed significant increase in apoptotic cells when H2228 
LR cells were treated with ceritinib plus panobinostat (C) Apoptosis assay 
showed significant increase in apoptotic cells when H3122 LR cells were 
treated with ceritinib plus panobinostat (D) Apoptosis-related markers were 
examined by western blot after treatment with panobinostat. (E) Cell cycle 
assay showed that ceritinib and panobinostat treatment induced arrest of the 
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cells at the G1 phase. (F) Panobinostat treatment regulated downstream 
effector genes of miR-34a and miR-449a and reversed EMT phenotype by 
downregulating N-cadherin and upregulating E-cadherin expression.
7. Combination of HDAC inhibitor and ceritinib induces enhanced 
antitumor efficacy in acquired resistant xenograft models
H3122 xenograft tumors were established in nude mice, and were treated with 
LDK378 75mg/kg to derive ceritinib-resistant tumors. Resistant tumors were 
randomized to four treatment groups (vehicle, LDK378 75mg/kg, LBH 50mg, 
LDK378 75mg/kg and LBH 50mg/kg), each group consisting of 5 mice. 
Consistent with the in vitro findings, combination treatment with LDK378 and 
LBH displayed superior antitumor efficacy compared with monotherapy of 
LBH. 
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Figure 7. Enhanced activity of panobinostat in combination with ceritinib 
in vivo (A) Ceritinib-resistant tumors were treated with vehicle, LDK378 
75mg/kg, LBH 50mg/kg, LDK378 75mg/kg and LBH 50mg/kg, as indicated. 
(B) Photographs of representative mice with tumors from each group (C) 
Photographs of excised tumors from each group
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IV. DISCUSSION
In this study, we discovered that H3K27ac remodeling and changes in 
miRNA expression are crucial events in ceritinib resistance. Reduced 
expression of miR-34a and miR-449a with decreased H3K27ac led to 
upregulation of AXL and EMT related genes in ceritinib resistant cells. 
Moreover, treatment of HDAC inhibitor, panobinostat increased H3K27ac 
signal and restored sensitivity to ceritinib. (Figure 7). To our knowledge, this 
is the first study to report epigenetic regulation of acquired resistance 
mechanism using in vitro, in vivo ALK-positive lung cancer models. 
Figure 8. Schematic diagram of ceritinib resistance mechanism 
involving epigenetic regulation of miRNAs
Although ceritinib is the treatment of choice in crizotinib-refractory 
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ALK-positive NSCLC patients, most patients eventually develop resistance. 
While various mechanisms of resistance to crizotinib have been known, only 
secondary mutations in the ALK gene have been identified as mechanisms of 
acquired resistance to ceritinib7, 42. To date, ALK G1202R, F1174C/V and 
most recently, G1123S mutation were identified in a patient with exhibiting 
resistance to ceritinib. These resistant mutations can be overcome by a highly 
potent, third-generation ALK inhibitor, such as lorlatinib. However, resistance 
mechanisms other than secondary mutations are largely unknown and 
strategies to overcome have not been investigated. 
In our study, H3122 LR and H2228 LR cells and xenograft model exhibited 
elevated expression of EMT-related genes. RNA sequencing of H3122 
parental and H3122 LR cells showed increased mRNA expression of AXL and 
its ligand, GAS6. In addition, EMT-associated transcriptional changes 
involving upregulation of vimentin and downregulation of E-cadherin were 
observed. In addition, EMT has been previously reported as an acquired 
resistance mechanism of crizotinib11, 12. Yet, our study uncovers a distinct 
mechanism of acquired resistance by identifying microRNAs which regulate 
AXL and EMT-related gene expression. 
MicroRNAs and their roles in therapy resistance have been previously 
studied in various cancers43-45. Regulation of EMT by miRNAs in 
ALK-positive cell line has been recently reported by Gao et al. that miR-200c 
directly targets ZEB1 and thereby increasing E-cadherin expression, which in 
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turn, suggests that miR-200c can prevent EMT in H2228 cells by targeting 
ZEB146 .  
Since epigenetic mechanisms have crucial roles in EMT, we focused on 
epigenetic changes in ceritinib resistance47. Through ChIP-seq, we noted that
H3K27ac peaks were decreased in H3122 LR cells compared to H3122 
parental cells, suggesting loss of enhancer activity during acquired resistance 
to ceritinib. Genome-wide H3K27ac profiles showed decreased H3K27ac 
signals in many genomic regions in LR cells and 5% of these regions were 
associated with miRNAs within 10kb. Among 188 downregulated miRNAs in 
resistant cells, decreased H3K27ac levels of miR-34a and miR-449a were 
notable. Expression levels of miR-34a and miR-449a, which downregulate 
AXL expression, were also decreased41. MiR-34a is known to antagonize 
many different oncogenic processes such as apoptosis, proliferation, invasion 
and migration48. MiR-449a is a potent inducer of cell death, cell cycle arrest, 
and/or cell differentiation41. They belong to the same family and are
structurally related. In our study, deacetylation of miR-34a and miR-449a led 
to altered expression of their target genes associated with EMT, apoptosis and 
cell cycle. Re-introduction of miR-34a and miR-449a sensitized H3122 LR 
cells to ceritinib. 
Intriguingly, panobinostat treatment induced synergistic anti-proliferative 
effects in ceritinib-resistant cells. Panobinostat is a potent, pan-HDAC 
inhibitor which blocks class I, II and IV HDACs. It is currently approved for 
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the treatment of relapsed and refractory multiple myeloma, in which both 
bortezomib and immunomodulatory drugs have failed 49. Panobinostat 
induced site-specific increase of H3K27ac, as represented by increased 
miR-449 expression. Our observations suggest that panobinostat in 
combination with ceritinib will overcome acquired resistance to ceritinib. 
Combination strategy of ceritinib and panobinostat is feasible since they do 
not have overlapping grade 3/4 toxicities. Ceritinib has gastrointestinal 
toxicities such as elevated liver enzymes and diarrhea, whereas panobinostat 
has hematological toxicities such as neutropenia and thrombocytopenia50. This 
provides a rationale for the development of HDAC inhibitor for clinical use of 
ALK-positive advanced NSCLC patients to either prevent or overcome 
resistance to ALK TKIs.     
V. CONCLUSION
H3K27ac remodeling and changes in miRNA expression such as miR-34a 
and miR-449a should be considered as a novel acquired resistance mechanism 
associated with ceritinib, and panobinostat may be a promising option for 
overcoming ceritinib resistance. 
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ABSTRACT(IN KOREAN)
miRNA-34a 와 miRNA-449a 의 후생유전학적 변화로 인한
epithelial-mesenchymal transition과 세리티닙에 대한 획득
내성 기전 규명
<지도교수  조 병 철>
연세대학교 대학원 의학과
임 선 민
EML4-ALK 양성 비소세포폐암 환자에서 ALK 타이로신 키나아제
억제제 치료 시 초기에는 우수한 반응을 보이나, 결국 약제
내성을 획득하게 된다. 비록 ALK 억제제에 대한 획득 내성 연
구들이 진행된 바 있지만, 현재까지 후성유전학적 기전에 대
한 연구는 전무하다. 본 연구에서는 세리티닙이라는 2세대
ALK 억제제에 대한 획득 기전 규명을 위해 RNA-seq, MBD-seq, 
ChIP-seq 통합 분석을 통해 내성 획득 세포의 전사체, DNA 메
틸화, 히스톤 아세틸화 등 후성 유전체 통합 분석을 실행하였
다. ALK 양성 내성 세포주에서 모세포주에 비해 H3K27ac 부위
에 탈 아세틸화가 두드러지게 나타나는 것을 확인하였고, AXL 
발현 증가와 상피-간엽전환 (epithelial-to-mesenchymal 
transition)이 발생하는 것을 확인하였다. H3K27 아세틸화 감
소와 함께 mRNA 발현이 감소하는 유전자들을 선별한 결과,
miR-34a와 miR-449a의 H3K27 탈아세틸화로 인하여 miR-34a와
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miR-449a의 발현이 감소하고, 이에 따라 이들이 하위로 조절
하는 AXL 과 mesenchymal 유전자들의 발현이 증가하는 기전을
규명하였다. 또한 AXL을 억제하거나 miR-34a 와 miR-449a를
외부에서 주입시켜 주었을 때 세리티닙에 대해 다시 민감성을
획득하였다. 히스톤 탈 아세틸화 효소 억제제인 Panobinostat 
에 의한 miR-34a 와 miR-449a의 탈 아세틸화 및 발현 조절이
가능한지 확인하기 위해 Panobinostat 처리 후 q-PCR, RNA-seq, 
ChIP-seq 분석을 수행하였고, Panobinostat 이 내성 세포주의
H3K27ac 부위에서 아세틸화를 증가시키는 것을 볼 수 있었다. 
Panobinostat을 세리티닙과 함께 내성세포주에 처리하였을 경
우 병용효과를 확인할 수 있었고, G1 arrest 유도 단백질로 알
려진 CDK inhibitor protein(CIP/KIP family)인 p21의 발현과, 
세포사멸 (Apoptosis) 관련 단백질인 cleaved PARP와 cleaved 
caspase 3의 발현을 증가시킨 것을 확인하였다. 또한 miR-34a 
및 miR-449 가 표적으로 하는 AXL 및 MET 등의 단백질 및
N-cadherin의 발현은 감소시켰고, 감소된 E-cadherin의 발현
을 다시 증가시켰다. 상기 결과들을 통해 H3K27ac 리모델링으
로 인한 miR-34a와 miR-449a 발현 감소가 세리티닙의 획득 내
성에 중요한 역할을 하며, 이를 극복하기 위한 새로운 치료
방법으로서 히스톤 탈 아세틸화 효소 억제제와 세리티닙의 병
용 요법에 대한 전략을 제시해준다.
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